Martingale Asset Management Reduces Stake in Eli Lilly

Hedge fund cuts holdings in pharmaceutical giant by 25.5% in Q3

Mar. 13, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Martingale Asset Management L.P. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 25.5% in the 3rd quarter, according to the company's latest 13F filing with the SEC. The hedge fund now owns 36,784 shares of the pharmaceutical company's stock, down from 49,396 shares held previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a market capitalization over $900 billion. Changes in major institutional investors' holdings can signal shifts in sentiment around the stock and provide insights into the broader market's view of the company's prospects.

The details

Martingale Asset Management sold 12,612 shares of Eli Lilly stock during the third quarter. The firm's total holdings in Eli Lilly are now valued at $28,066,000 as of the latest filing. The sale represents a 25.5% reduction in Martingale's position in the company.

  • Martingale Asset Management reduced its Eli Lilly stake in Q3 2026.

The players

Martingale Asset Management L.P.

A hedge fund that has reduced its holdings in pharmaceutical giant Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana.

Got photos? Submit your photos here. ›

The takeaway

Martingale Asset Management's decision to significantly cut its position in Eli Lilly suggests the hedge fund may have concerns about the company's future performance or valuation. However, Eli Lilly remains a dominant player in the pharmaceutical industry, and changes in institutional ownership do not necessarily indicate broader market sentiment.